India Price Cap Agency Considers Drug Packaging Cost Pass-Along
This article was originally published in PharmAsia News
Executive Summary
India's drug-pricing agency is expected to allow the pharmaceutical industry to pass on the increasing cost of packaging the products. The industry had proposed the pass-along as rising packaging costs figured larger in the cost of marketing the medicines. As a result, the National Pharmaceutical Pricing Authority asked drug makers to submit their actual costs so it can revise the cap on the price that can be charged at the retail level. Makers also have argued that part of the increased packaging cost, particularly for innovative and specialized drugs, is due to a need for packaging techniques to guard against counterfeits. (Click here for more
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.